Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
Muscle diseases.

Journal of clinical neuromuscular disease

Genge A, Shapira AH, Griggs RC.
PMID: 19078567
J Clin Neuromuscul Dis. 1999 Dec;1(2):114. doi: 10.1097/00131402-199912000-00015.

No abstract available.

Cite
Genge A, Shapira AH, Griggs RC. Muscle diseases. J Clin Neuromuscul Dis. 1999;1(2):114doi: 10.1097/00131402-199912000-00015.
Genge, A., Shapira, A. H., & Griggs, R. C. (1999). Muscle diseases. Journal of clinical neuromuscular disease, 1(2), 114. https://doi.org/10.1097/00131402-199912000-00015
Genge, A, et al. "Muscle diseases." Journal of clinical neuromuscular disease vol. 1,2 (1999): 114. doi: https://doi.org/10.1097/00131402-199912000-00015
Genge A, Shapira AH, Griggs RC. Muscle diseases. J Clin Neuromuscul Dis. 1999 Dec;1(2):114. doi: 10.1097/00131402-199912000-00015. PMID: 19078567.
Copy Download .nbib Format: NLM
Mitochondrial contribution to Parkinson's disease pathogenesis.

Parkinson's disease

Schapira AH, Gegg M.
PMID: 21687805
Parkinsons Dis. 2011;2011:159160. doi: 10.4061/2011/159160. Epub 2011 Apr 28.

The identification of the etiologies and pathogenesis of Parkinson's disease (PD) should play an important role in enabling the development of novel treatment strategies to prevent or slow the progression of the disease. The last few years have seen...

Cite
Schapira AH, Gegg M. Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis. 2011;2011:159160doi: 10.4061/2011/159160.
Schapira, A. H., & Gegg, M. (2011). Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinson's disease, 2011159160. https://doi.org/10.4061/2011/159160
Schapira, Anthony H V, and Gegg, Matthew. "Mitochondrial contribution to Parkinson's disease pathogenesis." Parkinson's disease vol. 2011 (2011): 159160. doi: https://doi.org/10.4061/2011/159160
Schapira AH, Gegg M. Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis. 2011;2011:159160. doi: 10.4061/2011/159160. Epub 2011 Apr 28. PMID: 21687805; PMCID: PMC3109314.
Copy Download .nbib Format: NLM
Corrigendum to "Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study" [Mol. Genet. Metab. 109 (2013) 221-223].

Molecular genetics and metabolism

McNeill A, Roberti G, Lascaratos G, Hughes D, Mehta A, Garway-Heath DF, Schapira AHV.
PMID: 28843379
Mol Genet Metab. 2014 Mar;111(3):408. doi: 10.1016/j.ymgme.2013.12.297. Epub 2014 Jan 21.

No abstract available.

Cite
McNeill A, Roberti G, Lascaratos G, et al. Corrigendum to "Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study" [Mol. Genet. Metab. 109 (2013) 221-223]. Mol Genet Metab. 2014;111(3):408doi: 10.1016/j.ymgme.2013.12.297.
McNeill, A., Roberti, G., Lascaratos, G., Hughes, D., Mehta, A., Garway-Heath, D. F., & Schapira, A. H. V. (2014). Corrigendum to "Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study" [Mol. Genet. Metab. 109 (2013) 221-223]. Molecular genetics and metabolism, 111(3), 408. https://doi.org/10.1016/j.ymgme.2013.12.297
McNeill, Alisdair, et al. "Corrigendum to "Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study" [Mol. Genet. Metab. 109 (2013) 221-223]." Molecular genetics and metabolism vol. 111,3 (2014): 408. doi: https://doi.org/10.1016/j.ymgme.2013.12.297
McNeill A, Roberti G, Lascaratos G, Hughes D, Mehta A, Garway-Heath DF, Schapira AHV. Corrigendum to "Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study" [Mol. Genet. Metab. 109 (2013) 221-223]. Mol Genet Metab. 2014 Mar;111(3):408. doi: 10.1016/j.ymgme.2013.12.297. Epub 2014 Jan 21. PMID: 28843379; PMCID: PMC5614915.
Copy Download .nbib Format: NLM
Case 262.

Radiology

Schapiro AH, Rattan MS, Moore RA, Dillman JR.
PMID: 30230998
Radiology. 2018 Oct;289(1):263-266. doi: 10.1148/radiol.2018161773.

History A 17-year-old white male adolescent was re-evaluated for a withheld cardiac condition initially detected during prenatal imaging at an outside institution. He had previously experienced intermittent episodes of shortness of breath, chest pain, and palpitations with exertion, but...

Cite
Schapiro AH, Rattan MS, Moore RA, et al. Case 262. Radiology. 2018;289(1):263-266doi: 10.1148/radiol.2018161773.
Schapiro, A. H., Rattan, M. S., Moore, R. A., & Dillman, J. R. (2018). Case 262. Radiology, 289(1), 263-266. https://doi.org/10.1148/radiol.2018161773
Schapiro, Andrew H, et al. "Case 262." Radiology vol. 289,1 (2018): 263-266. doi: https://doi.org/10.1148/radiol.2018161773
Schapiro AH, Rattan MS, Moore RA, Dillman JR. Case 262. Radiology. 2018 Oct;289(1):263-266. doi: 10.1148/radiol.2018161773. PMID: 30230998.
Copy Download .nbib Format: NLM
British neurology: a national focus.

Journal of neurology, neurosurgery, and psychiatry

Schapira AH, Marsden CD.
PMID: 8089688
J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1136. doi: 10.1136/jnnp.57.9.1136.
Free PMC Article

No abstract available.

Cite
Schapira AH, Marsden CD. British neurology: a national focus. J Neurol Neurosurg Psychiatry. 1994;57(9):1136doi: 10.1136/jnnp.57.9.1136.
Schapira, A. H., & Marsden, C. D. (1994). British neurology: a national focus. Journal of neurology, neurosurgery, and psychiatry, 57(9), 1136. https://doi.org/10.1136/jnnp.57.9.1136
Schapira, A H, and Marsden, C D. "British neurology: a national focus." Journal of neurology, neurosurgery, and psychiatry vol. 57,9 (1994): 1136. doi: https://doi.org/10.1136/jnnp.57.9.1136
Schapira AH, Marsden CD. British neurology: a national focus. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1136. doi: 10.1136/jnnp.57.9.1136. PMID: 8089688; PMCID: PMC1073146.
Copy Download .nbib Format: NLM
Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.

Journal of neurochemistry

Lee CY, Menozzi E, Chau KY, Schapira AHV.
PMID: 34618942
J Neurochem. 2021 Dec;159(5):826-839. doi: 10.1111/jnc.15524. Epub 2021 Oct 16.

The glucocerebrosidase 1 gene (GBA1), bi-allelic variants of which cause Gaucher disease (GD), encodes the lysosomal enzyme glucocerebrosidase (GCase) and is a risk factor for Parkinson Disease (PD). GBA1 variants are linked to a reduction in GCase activity in...

Cite
Lee CY, Menozzi E, Chau KY, et al. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes. J Neurochem. 2021;159(5):826-839doi: 10.1111/jnc.15524.
Lee, C. Y., Menozzi, E., Chau, K. Y., & Schapira, A. H. V. (2021). Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes. Journal of neurochemistry, 159(5), 826-839. https://doi.org/10.1111/jnc.15524
Lee, Chiao-Yin, et al. "Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes." Journal of neurochemistry vol. 159,5 (2021): 826-839. doi: https://doi.org/10.1111/jnc.15524
Lee CY, Menozzi E, Chau KY, Schapira AHV. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes. J Neurochem. 2021 Dec;159(5):826-839. doi: 10.1111/jnc.15524. Epub 2021 Oct 16. PMID: 34618942.
Copy Download .nbib Format: NLM
A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value.

Journal of neurology

Cosentino G, Avenali M, Schindler A, Pizzorni N, Montomoli C, Abbruzzese G, Antonini A, Barbiera F, Benazzo M, Benarroch EE, Bertino G, Cereda E, Clavè P, Cortelli P, Eleopra R, Ferrari C, Hamdy S, Huckabee ML, Lopiano L, Marchese Ragona R, Masiero S, Michou E, Occhini A, Pacchetti C, Pfeiffer RF, Restivo DA, Rondanelli M, Ruoppolo G, Sandrini G, Schapira AHV, Stocchi F, Tolosa E, Valentino F, Zamboni M, Zangaglia R, Zappia M, Tassorelli C, Alfonsi E.
PMID: 34417870
J Neurol. 2021 Aug 21; doi: 10.1007/s00415-021-10739-8. Epub 2021 Aug 21.

BACKGROUND: Parkinson's disease (PD) is a neurodegenerative disorder characterized by a combination of motor and non-motor dysfunction. Dysphagia is a common symptom in PD, though it is still too frequently underdiagnosed. Consensus is lacking on screening, diagnosis, and prognosis...

Cite
Cosentino G, Avenali M, Schindler A, et al. A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. J Neurol. 2021;doi: 10.1007/s00415-021-10739-8.
Cosentino, G., Avenali, M., Schindler, A., Pizzorni, N., Montomoli, C., Abbruzzese, G., Antonini, A., Barbiera, F., Benazzo, M., Benarroch, E. E., Bertino, G., Cereda, E., Clavè, P., Cortelli, P., Eleopra, R., Ferrari, C., Hamdy, S., Huckabee, M. L., Lopiano, L., Marchese Ragona, R., Masiero, S., Michou, E., Occhini, A., Pacchetti, C., Pfeiffer, R. F., Restivo, D. A., Rondanelli, M., Ruoppolo, G., Sandrini, G., Schapira, A. H. V., Stocchi, F., Tolosa, E., Valentino, F., Zamboni, M., Zangaglia, R., Zappia, M., Tassorelli, C., & Alfonsi, E. (2021). A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. Journal of neurology, . https://doi.org/10.1007/s00415-021-10739-8
Cosentino, Giuseppe, et al. "A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value." Journal of neurology vol. (2021). doi: https://doi.org/10.1007/s00415-021-10739-8
Cosentino G, Avenali M, Schindler A, Pizzorni N, Montomoli C, Abbruzzese G, Antonini A, Barbiera F, Benazzo M, Benarroch EE, Bertino G, Cereda E, Clavè P, Cortelli P, Eleopra R, Ferrari C, Hamdy S, Huckabee ML, Lopiano L, Marchese Ragona R, Masiero S, Michou E, Occhini A, Pacchetti C, Pfeiffer RF, Restivo DA, Rondanelli M, Ruoppolo G, Sandrini G, Schapira AHV, Stocchi F, Tolosa E, Valentino F, Zamboni M, Zangaglia R, Zappia M, Tassorelli C, Alfonsi E. A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. J Neurol. 2021 Aug 21; doi: 10.1007/s00415-021-10739-8. Epub 2021 Aug 21. PMID: 34417870.
Copy Download .nbib Format: NLM
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.

Journal of Parkinson's disease

Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ.
PMID: 34897099
J Parkinsons Dis. 2021 Dec 10; doi: 10.3233/JPD-212714. Epub 2021 Dec 10.

BACKGROUND: Glucocerebrosidase gene (GBA) mutations influence risk and prognosis of Parkinson's disease (PD), possibly through accumulation of glycosphingolipids, including glucosylceramide (GL-1). Venglustat is a novel, brain penetrant glucosylceramide synthase inhibitor.OBJECTIVE: Evaluate venglustat pharmacology, safety, and tolerability in patients with...

Cite
Peterschmitt MJ, Saiki H, Hatano T, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis. 2021;doi: 10.3233/JPD-212714.
Peterschmitt, M. J., Saiki, H., Hatano, T., Gasser, T., Isaacson, S. H., Gaemers, S. J. M., Minini, P., Saubadu, S., Sharma, J., Walbillic, S., Alcalay, R. N., Cutter, G., Hattori, N., Höglinger, G. U., Marek, K., Schapira, A. H. V., Scherzer, C. R., Simuni, T., Giladi, N., Sardi, S. P., Fischer, T. Z. (2021). Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson's disease, . https://doi.org/10.3233/JPD-212714
Peterschmitt, M Judith, et al. "Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial." Journal of Parkinson's disease vol. (2021). doi: https://doi.org/10.3233/JPD-212714
Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis. 2021 Dec 10; doi: 10.3233/JPD-212714. Epub 2021 Dec 10. PMID: 34897099.
Copy Download .nbib Format: NLM
Non-motor features of Parkinson disease.

Nature reviews. Neuroscience

Schapira AHV, Chaudhuri KR, Jenner P.
PMID: 28720825
Nat Rev Neurosci. 2017 Aug;18(8):509. doi: 10.1038/nrn.2017.91. Epub 2017 Jul 13.

This corrects the article DOI: 10.1038/nrn.2017.62.

Cite
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(8):509doi: 10.1038/nrn.2017.91.
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature reviews. Neuroscience, 18(8), 509. https://doi.org/10.1038/nrn.2017.91
Schapira, Anthony H V, et al. "Non-motor features of Parkinson disease." Nature reviews. Neuroscience vol. 18,8 (2017): 509. doi: https://doi.org/10.1038/nrn.2017.91
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017 Aug;18(8):509. doi: 10.1038/nrn.2017.91. Epub 2017 Jul 13. PMID: 28720825.
Copy Download .nbib Format: NLM
Bromide intoxication.

Canadian Medical Association journal

Schapira DV.
PMID: 20312755
Can Med Assoc J. 1976 Jul 17;115(2):156.

No abstract available.

Cite
Schapira DV. Bromide intoxication. Can Med Assoc J. 1976;115(2):156
Schapira, D. V. (1976). Bromide intoxication. Canadian Medical Association journal, 115(2), 156.
Schapira, D V. "Bromide intoxication." Canadian Medical Association journal vol. 115,2 (1976): 156.
Schapira DV. Bromide intoxication. Can Med Assoc J. 1976 Jul 17;115(2):156. PMID: 20312755; PMCID: PMC1878549.
Copy Download .nbib Format: NLM
Mitochondria in the etiology of Parkinson's disease.

Handbook of clinical neurology

Schapira AH.
PMID: 18808929
Handb Clin Neurol. 2007;83:479-91. doi: 10.1016/S0072-9752(07)83022-3.

No abstract available.

Cite
Schapira AH. Mitochondria in the etiology of Parkinson's disease. Handb Clin Neurol. 2007;83:479-91doi: 10.1016/S0072-9752(07)83022-3.
Schapira, A. H. (2007). Mitochondria in the etiology of Parkinson's disease. Handbook of clinical neurology, 83479-91. https://doi.org/10.1016/S0072-9752(07)83022-3
Schapira, Anthony H V. "Mitochondria in the etiology of Parkinson's disease." Handbook of clinical neurology vol. 83 (2007): 479-91. doi: https://doi.org/10.1016/S0072-9752(07)83022-3
Schapira AH. Mitochondria in the etiology of Parkinson's disease. Handb Clin Neurol. 2007;83:479-91. doi: 10.1016/S0072-9752(07)83022-3. PMID: 18808929.
Copy Download .nbib Format: NLM
Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release.

Parkinson's disease

Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M.
PMID: 24800101
Parkinsons Dis. 2014;2014:467131. doi: 10.1155/2014/467131. Epub 2014 Apr 01.

Background. The minimal clinically important difference (MCID) is the smallest change in an outcome measure that is meaningful for patients. Objectives. To calculate the MCID for Unified Parkinson's Disease Rating Scale (UPDRS) scores in early Parkinson's disease (EPD) and...

Cite
Hauser RA, Gordon MF, Mizuno Y, et al. Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014;2014:467131doi: 10.1155/2014/467131.
Hauser, R. A., Gordon, M. F., Mizuno, Y., Poewe, W., Barone, P., Schapira, A. H., Rascol, O., Debieuvre, C., & Fräßdorf, M. (2014). Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinson's disease, 2014467131. https://doi.org/10.1155/2014/467131
Hauser, Robert A, et al. "Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release." Parkinson's disease vol. 2014 (2014): 467131. doi: https://doi.org/10.1155/2014/467131
Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M. Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014;2014:467131. doi: 10.1155/2014/467131. Epub 2014 Apr 01. PMID: 24800101; PMCID: PMC3995302.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries